GlaxoSmithKline reported a total income of Rs. 1024.84 crore during the period ended September 30, 2021, as compared to Rs. 821.72 crores during the period ended June 30, 2021. The company has reported a total income of Rs. 888.36 crore during the period ended September 30, 2020.

It posted a net profit of Rs. 204.24 crore for the period ended September 30, 2021. as against a net profit of Rs. 121.08 crore for the period ended June 30, 2021. The company has posted a net profit of Rs.76.47 crore for the period ended September 30, 2020.

GlaxoSmithKline  has reported a total income of Rs.1846.56 crore during the 6 months ended September 30, 2021, as compared to Rs.1594.87 crores during the 6 months ended September 30, 2020.

The company has posted a net profit of Rs.325.32 crore for the 6 months ended September 30, 2021, as against a net profit of Rs.187.30 crore for the 6 months ended September 30, 2020.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals said, "We delivered a strong performance in 02. As the acute market showed signs of recovery, our established brands grew in their respective therapeutic portfolios. Augmentin and Calpol regained their place amongst the top five brands in the Indian Pharmaceuticals Market (IPM). Our promoted portfolio also gained market share, while products from our innovation and speciality pipeline continued to make inroads to serve more patients. We continue to find ways to leverage innovations in emerging technologies and deliver even greater value to our shareholders in alignment with our priorities. We also improved our operational efficiencies, driven by sales growth and cost rationalisation. We also improved our cash position backed by working capital improvements. We expect this positive momentum to continue through the second half of the year driving us towards the better end of a meaningful performance improvement. Our clear priority is to focus on execution, unlocking the value for patients and delivering step-change growth and performance."